Related Experiment Video

Updated: Apr 18, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis

Filippa Pettersson1, Sonia V Del Rincon1, Audrey Emond1

  • 1Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Cancer Research
|January 23, 2015
PubMed

Insights

Ribavirin, an eIF4E inhibitor, effectively suppresses breast tumor growth and metastasis. This drug reduces cancer cell invasiveness by impacting matrix metalloproteinases and epithelial-to-mesenchymal transition, offering a new strategy for metastatic breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The translation initiation factor eukaryotic initiation factor 4E (eIF4E) is an oncogene frequently overexpressed in breast cancers.
  • Overexpression of eIF4E correlates with tumor progression and metastasis in breast cancer patients.

Purpose of the Study:

  • To investigate the therapeutic potential of ribavirin, a pharmacologic inhibitor of eIF4E, in preclinical models of breast cancer.
  • To elucidate the mechanisms by which eIF4E inhibition affects breast tumor growth, invasion, and metastasis.

Main Methods:

  • Utilized murine models of primary breast tumor formation and lung metastasis.
  • Assessed the effects of ribavirin administration and eIF4E silencing on tumor growth, invasiveness, and metastatic potential.
  • Analyzed the activity of matrix metalloproteinases (MMP-3 and MMP-9) and epithelial-to-mesenchymal transition (EMT) markers.

Main Results:

  • Ribavirin treatment safely and potently suppressed primary breast tumor formation in vivo.
  • Ribavirin administration significantly reduced lung metastasis development in an invasive breast cancer model.
  • eIF4E inhibition decreased breast cancer cell invasiveness and metastatic capability, associated with reduced MMP-3 and MMP-9 activity.
  • Ribavirin treatment and eIF4E silencing suppressed key features of epithelial-to-mesenchymal transition.

Conclusions:

  • Pharmacologic inhibition of eIF4E with ribavirin demonstrates significant preclinical efficacy against breast tumor growth and metastasis.
  • The findings suggest that targeting eIF4E could be a viable therapeutic strategy for treating metastatic breast cancer.
  • Further clinical evaluation of ribavirin for solid tumors, including metastatic breast cancer, is warranted.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
7.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.5K